SLU-PP-332 is an investigational compound that is a selective agonist of the REV-ERBα receptor, which plays a role in the regulation of circadian rhythms, metabolism, and inflammatory processes. It is gaining attention in experimental models related to energy homeostasis, inflammation reduction, and neurodegeneration.
Active ingredient content
250 mcg SLU-PP-332 in 1 capsule
Packaging
60 capsules in a resealable container
Storage
In a dry and dark place, at room temperature
Molecular formula
C22H23N3O2S
Molecular weight
393.51 g mol⁻¹
Other names
SLUPP-332, REV-ERB agonist
In laboratory studies, SLU-PP-332 is associated with research in areas such as:
- modulation of circadian rhythm and sleep cycles,
- reduction of inflammatory markers and neuroinflammation,
- improving metabolic balance and glucose tolerance,
- adjustment of lipid profile and cholesterol levels,
- potential impact on neurodegenerative diseases.
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is SLU-PP-332
SLU-PP-332 is a synthetic molecule developed as an agonist of the nuclear receptor REV-ERBα, which is involved in the regulation of the biological clock, lipid and glucose metabolism, and inflammation. REV-ERB receptors are a research target in the areas of sleep disorders, obesity, neurodegeneration, and immunological responses.
How does SLU-PP-332 work?
SLU-PP-332 binds and activates the REV-ERBα receptor, thereby influencing the expression of genes associated with circadian rhythms, inflammatory pathways, and metabolism. By activating this receptor, it can reduce the production of pro-inflammatory cytokines, improve insulin sensitivity, and optimize energy expenditure. It is also thought to have effects on neuroinflammation and behavioral models of anxiety.
Effects studied
-
Anti-inflammatory effects: Suppression of cytokines such as IL-6 and TNF-α in inflammatory models.
-
Support for circadian synchronization: Affects the expression of genes such as BMAL1, PER2 and CRY1.
-
Reduction of fat mass: Observed improvement in lipid profile and insulin sensitivity.
-
Neuroprotection: In preclinical studies, it has shown a positive effect on neuroinflammation.
-
Potential in mood disorders: REV-ERB agonists are being investigated in relation to anxiety and depression.
Dosage in studies
The values listed are derived solely from research studies and are not intended for real-world use outside of a laboratory environment.
-
Dose: 100–300 mcg/kg daily (mainly in in vivo models)
-
Form: oral (capsule form or solution)
-
Frequency: 1× daily
-
Duration: 10–28 days according to protocol
Possible side effects
- Mood swings or irritability with long-term use
- Mild gastrointestinal discomfort
- Drowsiness or decreased alertness at higher doses
Resources
- Siracusa, R. et al. (2022). REV-ERB Agonists: A New Frontier in Inflammation Control
- Sulli, G. et al. (2018). REV-ERB Agonists Suppress Inflammation in Neurodegenerative Models
- Solt, LA et al. (2012). REV-ERB Activation Controls Metabolism and Circadian Behavior
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is a summary of existing scientific literature and is for educational purposes only.
Sale
Sale
Sale
